Grifols Sa Stock Earnings Reports

Grifols delivered a solid start to 2026 with Q1 revenue of EUR 1.7bn (+3.3% cc) and adjusted EBITDA of EUR 404m (EUR 381m reported), driven by strong Biopharma performance—notably immunoglobulins (IG) which grew double-digits—and improving free cash flow trends. Management reiterated full-year 2026 guidance: drive adjusted EBITDA margin to at least 25%, deliver 5–9% adjusted EBITDA growth (cc), and improve free cash flow toward the EUR 500–575m target. Key strategic priorities include: 1) optimizing the Biopharma product mix (IG growth, balancing albumin and specialty proteins), 2) scaling Egypt plasma collections (target ~1m liters in 2026, ~3m by 2029) to lower cost-per-liter (CPL) and rebalance global sourcing, 3) continuing the Biotest turnaround and integrating its products, 4) Diagnostics product launches (Barcelona blood-typing platform in Q2 ’26; ISARD immunoassay strategy) and 5) strict financial discipline. Diagnostics reported a temporary headwind from the dissolution of the Quidel Ortho joint venture but will receive a USD 65m compensation over three years and gains autonomy for its ISARD and Barcelona platforms. Management highlighted operational actions in the U.S. plasma network (closure/consolidation of underperforming donor centers) and successful refinancing that materially improved the debt maturity profile and liquidity (revolver > $2bn, extension of maturities past 2028). The company is exploring a potential IPO of a portion of its U.S. Biopharma business (early stage; no details provided). Capital allocation optionality has improved (redeemed EUR 500m of 7.5% bonds, potential for buybacks in future subject to Board approval). Near-term headwinds: albumin price/volume dynamics in China (stabilizing but weighing on H1), FX (weaker USD impacts revenue translation), and Q1 seasonality/working capital build. Management remains confident in executing 2026 plan and reducing leverage over time.